ReCor Medical

Develops ultrasound technology for hypertension treatment

Palo Alto, California, United States

About ReCor Medical

ReCor Medical focuses on treating hypertension, a condition that affects over 1 billion people globally. The company has created the Paradise System, which utilizes non-focused ultrasound technology to perform renal denervation, a procedure that targets kidney nerves to help lower blood pressure. This system is particularly beneficial for patients who do not respond well to standard blood pressure medications. ReCor Medical is dedicated to clinical research and development to ensure the safety and effectiveness of its technology, and it generates revenue through the sale of its medical devices and partnerships with healthcare providers. The company is also involved in significant clinical trials, such as the RADIANCE Global Program, aimed at demonstrating the benefits of renal denervation for hypertension treatment. ReCor Medical's goal is to provide a new treatment option for high blood pressure, addressing a major global health issue.

Palo Alto, CaliforniaHeadquarters
2009Year Founded
$29.2MTotal Funding
DEBTCompany Stage
HealthcareIndustries
51-200Employees

Risks

Competition from Medtronic may impact ReCor's market share and pricing.
New CEO could lead to strategic shifts disrupting current operations.
Regulatory setbacks could delay Paradise System's market entry and revenue.

Differentiation

ReCor Medical's Paradise System uses non-focused ultrasound for renal denervation.
The system targets kidney nerves to reduce high blood pressure effectively.
ReCor Medical focuses on patients unresponsive to traditional antihypertensive medications.

Upsides

FDA approval boosts ReCor's market entry and adoption in the US.
Global renal denervation market projected to grow at 35% CAGR until 2030.
Increased interest in non-pharmacological hypertension treatments benefits ReCor's technology.

Funding

Total raised$29.18 M
Latest valuation$75.00 M
StageDEBT
DEBT
5/31/2016
$10